Since Russia launched its full-scale invasion of Ukraine four years ago, Lozko has been treating patients under wartime conditions. https://cancerletter.com/the-cancer-letter/20260403_2/

Guest editorial by Nicholas Richardson, DO, MPH: In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” https://cancerletter.com/guest-editorial/20260403_3/

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients https://cancerletter.com/drugs-and-targets/20260403_8b/

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows https://cancerletter.com/clinical-roundup/20260403_7a/

The Dietary Guidelines for Americans, or DGA, rewritten every five years, are ubiquitous in American life. https://cancerletter.com/news-analysis/20260403_1/

Marshall Posner named associate director, clinical investigations, at TGH Cancer Institute https://cancerletter.com/in-brief/20260403_6b/

Radiation oncologists hit hard after Medicare cuts, ASTRO survey finds (@astro-org.bsky.social) https://cancerletter.com/cancer-policy/20260403_5c/

NCI Trials for April 2026 https://cancerletter.com/nci-trials/20260403_9/

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol https://cancerletter.com/news-analysis/20260403_1/

FDA approves Tecartus for r/r mantle cell lymphoma https://cancerletter.com/drugs-and-targets/20260403_8a/

Machine-learning tool may predict serious transplant complications months before symptoms appear Blood biomarkers power a new AI-based approach to identifying risk after transplant. Guest editorial by MUSC Hollings Cancer Center. https://cancerletter.com/sponsored-article/20260327_7/

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most Draft guidance consolidates trial design updates for developers. Guest editorial by Nicholas Richardson, DO, MPH https://cancerletter.com/guest-editorial/20260403_3/

Daniela Matei named director of Houston Methodist Neal Cancer Center https://cancerletter.com/in-brief/20260403_6a/

Ukrainian oncologists press on in year four of wartime disruptions Amid missiles and blackouts, “you cannot put your life on a pause forever.” https://cancerletter.com/the-cancer-letter/20260403_2/

Trump imposes up to 100% tariff on some brand name pharmaceutical companies https://cancerletter.com/cancer-policy/20260403_5b/

The Cancer Letter Podcast nominated for 30th annual Webby Awards https://cancerletter.com/editorial/20260403_4/

@mayoclinic.org pilot study demonstrates safety, feasibility of delivering chemotherapy at home https://cancerletter.com/clinical-roundup/20260327_10c/

On The Directors podcast, Nicholas Petrelli and Dario Altieri said that the strain on scientific funding from the federal government is one of the top issues keeping them up at night. (@wistar.org) https://cancerletter.com/podcastc/20260327_1/

W. Kimryn Rathmell: "Understanding early-onset cancers demands a multidimensional approach." https://cancerletter.com/trials-and-tribulations/20260327_2/

Alice Lin Pomponio named SVP of corporate development and strategic partnerships at PICI https://cancerletter.com/in-brief/20260327_9d/

"We really do not fully understand the underlying risk factor for the increase in mortality rates for colorectal cancer," said Ahmedin Jemal of @acscan.bsky.social. https://cancerletter.com/clinical/20260327_4/

“Mike Bishop was a titan of science and a pillar of the UCSF community. His research forever changed our understanding of cancer and its underlying causes," writes Sam Hawgood, UCSF chancellor (@ucsanfrancisco.bsky.social). https://cancerletter.com/obituary/20260327_5/

We’re officially nominated at the Webby Awards — and this one means everything. Independent. Purpose-driven. Built to inform, challenge, and tell the stories that matter in cancer research and care. Now let’s bring it home. Vote for us. https://wbby.co/57449N

VCU Massey researchers lead international effort to produce multi-omic digital atlas of oral tissues (@vcumassey.bsky.social) https://cancerletter.com/clinical-roundup/20260327_10d/

Colorectal cancer is now the leading cause of cancer death in patients under 50. Why aren’t 45-year-olds getting their recommended CRC screenings? (@acscan.bsky.social) https://cancerletter.com/clinical/20260327_4/

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma https://cancerletter.com/drugs-and-targets/20260327_11a/

Michael Bishop, Nobel-winning cancer researcher, dies at 90 https://cancerletter.com/obituary/20260327_5/

UC San Francisco Chancellor Emeritus J. Michael Bishop, a pioneering microbiologist who shared the 1989 Nobel Prize in Physiology or Medicine for discovering that every cell in the body harbors genes that can cause cancer, died March 20. He was 90. https://cancerletter.com/obituary/20260327_5/

FDA withdraws proposed rule that would have banned minors from using tanning beds https://cancerletter.com/cancer-policy/20260327_8b/

Lisa Roth named director of pediatric hematology-oncology at Hassenfeld Children’s Hospital at NYU Langone (@nyulangone.bsky.social) https://cancerletter.com/in-brief/20260327_9b/

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds (@kffhealthnews.org) https://cancerletter.com/cancer-policy/20260327_8d/

Dario Altieri (@wistar.org) says building the Wistar-Christiana partnership was a unique experience in his career as a cancer director. https://cancerletter.com/podcastc/20260327_1/

Guest editorial by Richard M. Goldberg: "For patients with the most common form of metastatic colorectal cancer (microsatellite-stable disease) that affects 95% of patients, today’s immunotherapies are largely ineffective." https://cancerletter.com/trials-and-tribulations/20260327_3/

Monica Baskin named interim director of VCU Massey Comprehensive Cancer Center https://cancerletter.com/in-brief/20260327_9c/

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds (@mdanderson.bsky.social) https://cancerletter.com/clinical-roundup/20260327_10b/

Three decades ago, colorectal cancer was the fifth leading cause of cancer death in patients under 50 years old. For a physician treating the average 45-year-old, colorectal cancer was not a diagnosis that immediately came to mind. (@acscan.bsky.social) https://cancerletter.com/clinical/20260327_4/

Guest editorial by Sylvester Comprehensive Cancer Center: "Cancer research increasingly demands environments that mirror the biology it seeks to understand: Complex, adaptive and deeply interconnected." https://cancerletter.com/sponsored-article/20260327_6/

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC https://cancerletter.com/drugs-and-targets/20260327_11c/

FDA issues draft guidance to reduce animal testing https://cancerletter.com/cancer-policy/20260327_8c/

"Seeing this spike in early-onset cancers, our response should be to adjust healthcare delivery to meaningfully impact disability-adjusted life years on a population scale," writes W. Kimryn Rathmell in a guest editorial. https://cancerletter.com/trials-and-tribulations/20260327_2/

"We are caring for patients in their 20s, 30s, and 40s—often raising young children while facing an incurable disease that threatens to cut their lives short," writes Richard M. Goldberg in a guest editorial. https://cancerletter.com/trials-and-tribulations/20260327_3/

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer https://cancerletter.com/drugs-and-targets/20260327_11b/

Talzenna + Xtandi combination significantly improves radiographic PFS in metastatic prostate cancer https://cancerletter.com/clinical-roundup/20260327_10a/

Nicholas Petrelli and Dario Altieri (@wistar.org) appeared together on The Directors, a monthly series which focuses on the problems that keep directors of cancer centers up at night. https://cancerletter.com/podcastc/20260327_1/

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes (@wistar.org) https://cancerletter.com/podcastc/20260327_1/

Beyond the lab: Engineering collaboration in modern cancer research. Guest editorial by Sylvester Comprehensive Cancer Center. https://cancerletter.com/sponsored-article/20260327_6/

Roy Herbst named director at Dartmouth Cancer Center https://cancerletter.com/in-brief/20260327_9a/

FDA issues warning letter to ImmunityBio over misleading claims about cancer drug https://cancerletter.com/cancer-policy/20260327_8a/

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients. Guest editorial by W. Kimryn Rathmell, MD, PhD, MMHC. https://cancerletter.com/trials-and-tribulations/20260327_2/

In the era of immunotherapy, response rate alone fails to predict true patient benefit. Regulators must adapt. Guest editorial by Richard M. Goldberg, MD. https://cancerletter.com/trials-and-tribulations/20260327_3/